AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson’s disease by unknown
METHODOLOGY ARTICLE Open Access
AAV1/2-induced overexpression of A53T-α-
synuclein in the substantia nigra results in
degeneration of the nigrostriatal system
with Lewy-like pathology and motor
impairment: a new mouse model for
Parkinson’s disease
Chi Wang Ip1* , Laura-Christin Klaus1, Akua A. Karikari1, Naomi P. Visanji2, Jonathan M. Brotchie3,
Anthony E. Lang2,3,4,5, Jens Volkmann1 and James B. Koprich3
Abstract
α-Synuclein is a protein implicated in the etiopathogenesis of Parkinson’s disease (PD). AAV1/2-driven
overexpression of human mutated A53T-α-synuclein in rat and monkey substantia nigra (SN) induces degeneration
of nigral dopaminergic neurons and decreases striatal dopamine and tyrosine hydroxylase (TH). Given certain
advantages of the mouse, especially it being amendable to genetic manipulation, translating the AAV1/2-A53T
α-synuclein model to mice would be of significant value. AAV1/2-A53T α-synuclein or AAV1/2 empty vector (EV)
at a concentration of 5.16 x 1012 gp/ml were unilaterally injected into the right SN of male adult C57BL/6 mice.
Post-mortem examinations included immunohistochemistry to analyze nigral α-synuclein, Ser129 phosphorylated
α-synuclein and TH expression, striatal dopamine transporter (DAT) levels by autoradiography and dopamine levels
by high performance liquid chromatography. At 10 weeks, in AAV1/2-A53T α-synuclein mice there was a 33%
reduction in TH+ dopaminergic nigral neurons (P < 0.001), 29% deficit in striatal DAT binding (P < 0.05), 38% and
33% reductions in dopamine (P < 0.001) and DOPAC (P < 0.01) levels and a 60% increase in dopamine turnover
(homovanilic acid/dopamine ratio; P < 0.001). Immunofluorescence showed that the AAV1/2-A53T α-synuclein
injected mice had widespread nigral and striatal expression of vector-delivered A53T-α-synuclein. Concurrent
staining with human PD SN samples using gold standard histological methodology for Lewy pathology detection
by proteinase K digestion and application of specific antibody raised against human Lewy body α-synuclein (LB509)
and Ser129 phosphorylated α-synuclein (81A) revealed insoluble α-synuclein aggregates in AAV1/2-A53T α-synuclein
mice resembling Lewy-like neurites and bodies. In the cylinder test, we observed significant paw use asymmetry in the
AAV1/2-A53T α-synuclein group when compared to EV controls at 5 and 9 weeks post injection (P < 0.001; P < 0.05).
These data show that unilateral injection of AAV1/2-A53T α-synuclein into the mouse SN leads to persistent motor
deficits, neurodegeneration of the nigrostriatal dopaminergic system and development of Lewy-like pathology, thereby
reflecting clinical and pathological hallmarks of human PD.
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Introduction
Parkinson’s disease (PD) is the second most common
neurodegenerative disorder with pathological hallmarks
consisting of degeneration of dopaminergic neurons
within the substantia nigra (SN), loss of dopaminergic
terminals projecting into the striatum and accumulation
of insoluble protein aggregates, termed Lewy bodies and
Lewy neurites. The latter two are composed of several
proteins with α-synuclein (aSyn) being the most abun-
dant component [18]. The physiologic role of aSyn
remains to be completely understood with reports
suggesting a function in synaptic transmitter release due
to its relationship with presynaptic vesicles [1, 4]. The
pathogenic role of insoluble aSyn in PD is even less clear
[3], however the fact that hereditary forms of PD can be
caused by duplication, triplication and missense muta-
tions in the aSyn encoding gene (e.g. A53T [22]), A30P
[16]) has strongly linked this protein to the pathogenesis
of PD [10, 16, 22]. Based on these observations, numer-
ous mouse models for PD with pathogenic aSyn expres-
sion have been generated. There are strains of transgenic
mice that express human mutated A53T-aSyn, A30P-
aSyn or both [7]. Although these mice mimic some
aspects of the human disease, including aSyn accumula-
tion in neurons of the SN, the major drawback in most
of these models is the lack of reproducible nigrostriatal
damage [7] and the timeframes to induce any degenera-
tive changes are long and variable. In addition to trans-
genic PD models, several gene delivery based animal
models of synucleinopathies have been generated by
using lentiviral [17] and adeno-associated vectors (AAV),
the latter demonstrating a high affinity for dopaminergic
neurons [27, 29]. Non-human primates and rats develop
PD-related histological and behavioural features from
AAV driven overexpression of mutated A53T-aSyn,
including early, within 6-16 weeks, dopaminergic neuron
loss in the SN [9, 12–14]. In rats, injection of an AAV1/
2 vector that contained human mutated A53T-aSyn
cDNA provides a rapid, within 6 weeks, and progressive
course of dopaminergic nigrostriatal degeneration that is
accompanied by aSyn aggregates. By using a chimeric
approach, this vector combines the advantages of AAV
serotype 2, high neuronal tropism and ability to produce
high titers, with that of AAV serotype 1, i.e. excellent
ability to penetrate brain tissue [13, 14]. Attempts have
been made with different AAV serotypes in mice to
generate PD models but these either demonstrated resili-
ence to aSyn-induced neurodegeneration by showing no,
or only slight, dopaminergic neuronal loss after relatively
long exposure times [5, 8, 25, 30] or have been so
aggressive as to produce high levels of neurodegenera-
tion without definite evidence of Lewy pathology that
did not model early PD [21, 24]. In view of the advan-
tages of knock-out or transgenic mouse models for
studying molecular mechanisms of neurodegeneration
and resilience our aim was to translate the AAV1/2-




43 male wild-type (wt) mice on C57BL/6 background
weighting 24–30 g were purchased from Charles River
Laboratories, Sulzfeld, Germany and investigated at the
age of 12 weeks. Mice were kept in near pathogen-free
environment under standard conditions (21 °C, 12 h/
12 h light-dark cycle).
Human midbrain sections
Human tissue was obtained from the Canadian Brain
Tissue Bank, and donated for research purposes follow-
ing informed consent. PD nigra was obtained from an
80-year-old male with an 11-year clinical history of PD.
Post mortem analysis revealed diffuse Lewy pathology
with neuronal nigral degeneration. Control tissue was
obtained from a 77-year-old male with no history of
neurologic disease and no evidence of neurodegenerative
changes on postmortem. 4 μm sections obtained from
formalin fixed paraffin embedded blocks were cut for
staining.
Adeno-associated vectors (AAV) 1/2 serotype injection
AAV1/2 were designed as described by Koprich et al.,
2010 [14]. Deeply anaesthetized mice were stereotactic-
ally injected unilaterally into the right SN with a micro-
injector (Stoelting, Kiel, Wisconsin, USA) at a rate of
0.5 μl/min with either 1.5 μl of empty AAV1/2 (empty
vector; EV) or 1.5 μl AAV1/2 expressing human mutated
A53T-aSyn both at a concentration of 5.16 x 1012
genomic particles (gp)/ml. According to the mouse brain
atlas of Paxinos and Franklin (Paxinos and Franklin, The
Mouse Brain in Stereotaxic Coordinates, Second Edition,
2001) the coordinates from Bregma: AP -3.1 mm; ML
-1.4 mm; DV -4.4 mm were applied for injection. 22
mice were injected with AAV1/2-A53T-aSyn, 21 mice
with AAV1/2-EV.
Behavioral studies
Spontaneous forepaw use was assessed by using the
cylinder test before, 5 and 9 weeks after AAV1/2 injec-
tion. Briefly, mice were placed into a transparent plexi-
glass cylinder of 12 cm diameter and 30 cm height in
front of two mirrors and were video recorded for a dur-
ation of 10 min. The videos were scored post-hoc by an
observer blinded to the treatment condition according
to the description by Schallert et al., 2000 [23]. Each
rearing of the mice was analyzed for the number of
touches of the inner surface of the cylinder with either
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the right (ipsilateral), the left (contralateral) or both
forepaws simultaneously. The final data was presented
as percentage of the ipsilateral (right) forepaw use by
calculation with the equation: {(ipsilateral paw + 0.5 both
paws) / (ipsilateral paw + contralateral paw + both paws)}
x 100. The calculated percentage declares the preference
of the forepaw use as follows: 50% = symmetric use of
both forepaws; <50% = preference of the left forepaw;
>50% preference of the right forepaw.
Tissue processing and immunohistochemistry
10 weeks after AAV1/2 injection mice were transcar-
dially perfused with 0.1 M phosphate buffered saline
(PBS). Fresh mouse brains were dissected in coronal
plane with a brain matrix slicer at the region of
+0.14 mm from Bregma (figure 30 Paxinos and Franklin
mouse brain atlas). The ventral part including the ven-
tral striatum was snap frozen in liquid dry ice-cooled
isopentane for HPLC analysis, dopamine transporter
(DAT) autoradiography and immunostaining for dopa-
minergic terminals. The dorsal part including the middle
and dorsal striatum as well as the SN was immersion-
fixed in 4% paraformaldehyde (PFA) in 0.1 M PBS for
two days and cryo-protected in 30% sucrose/0.1 M PBS
solution for another 2 days followed by freezing of the
tissue in liquid dry ice-cooled isopentane.
Tyrosine hydroxylase (TH) staining was used to label
dopaminergic fibers in 10 μm coronal cryo-sections of the
striatum (Paxinos and Franklin: figure 23). Sections were
preincubated for 30 min in 5% normal bovine serum
(BSA) in 0.1 M PBS and then incubated with rabbit anti-
mouse TH antibody (abcam, Cambridge, UK) diluted in
1% BSA/PBS for overnight at 4 °C. To visualize the
primary antibody, a biotinylated secondary antibody to
rabbit Igs was applied for 1 h, followed by avidin/biotin
reagent (Dako, High Wycombe, UK) before incubation
and staining with diaminobenzidine-HCl (DAB) and H2O2.
For unbiased stereology 40 μm PFA-fixed cryo-
sections were serially cut in the coronal plane. Two
series were preincubated for 1 h in 10% normal goat
serum (NGS)/2% BSA/0.5% Triton X-100 in 0.1 M PBS
on a shaker and then incubated with either rabbit anti-
mouse TH (abcam, Cambridge, UK) or mouse anti-
NeuN antibody (Merck, Millipore, CA, USA) diluted in
2% NGS/2% BSA/0.5% Triton X-100 in 0.1 M PBS for
overnight at 4 °C. Secondary antibodies against either
rabbit or mouse Igs was applied for 2 h followed by
avidin/biotin reagent and incubation and staining with
DAB and H2O2.
For TH/aSyn immunofluorescence double staining,
PFA-fixed sections were blocked with 10% NGS and 2%
BSA for 1 h at room temperature (RT). Sections were
then simultaneously incubated overnight at 4 °C with
rabbit anti-mouse TH (abcam, Cambridge, UK) and
mouse anti-human aSyn (Invitrogen, Maryland, USA).
This was followed by incubation with fluorescence
labelled goat anti-mouse Cy2 and goat anti-rabbit Cy3
secondary antibodies (Jackson ImmunoResearch
Laboratories Inc. Pennsylvania, USA) for 2 h at RT.
DAPI nuclear staining (Sigma Missouri, USA) was
subsequently performed at RT for 20 min.
Analysis of dopaminergic fibers and unbiased stereology
Density of TH+ fibers was measured in striatum by
optical density analysis (NIH ImageJ software) after
transforming colour into 8-bit greyscale images and
calculated as the difference between right and left
striatal optical density and the non-specifically stained
corpus callosum. Four striata slices per mouse were
analyzed.
The optical fractionator method of the Stereo
Investigator software package (version 11.07; Micro-
BrightField Biosciences, Williston, VT) was used for
unbiased stereological estimation of dopaminergic and
total neuronal numbers (NeuN+) in the SN. The inves-
tigator was blinded to treatment groups. Seven sections
per animal on average extending the rostral to caudal
portions of the SN pars compacta and reticulata were
used for quantification. The sections were separated by
160 μm (1/4 series) and TH-immunoreactive neurons
in both SN pars compacta and reticulata were included
within each selected region. Counting parameters were:
grid size 110 x 110 μm, counting frame 50 x 50 μm and
2 μm guard zone. Actual mounted thickness was deter-
mined by randomly selecting sections and determining
thickness at three counting sites. Sections were ana-
lyzed with a 100x/1.25 numerical aperture objective on
a BX53 microscope (Olympus). Gundersen coefficient
of error for m = 1 were all less than or equal to 0.09 for
each section counted.
Autoradiography
Striatal DAT level were examined from fresh-frozen
tissue sections using [125I]-RTI-121 binding autoradiog-
raphy as described [13]. In brief, slides first were incu-
bated in binding buffer containing 50 mM Tris, 120 mM
NaCl and 5 mM KCl at RT. Afterwards the sections
were placed in the same buffer with additional 50 pM
[125I]-RTI-121 (Perkin-Elmer, specific activity 2200 Ci/
mmol) for a duration of 2 h at 25 °C. We defined non-
specific binding as that observed in the presence of
100 mM GBR 12909 (Tocris Bioscience). Slides were
washed in ice-cold binding buffer, followed by rinsing in
ice-cold distilled water and dried. After this slides were
apposed to autoradiographic film (Kodak) together with
[125I]- microscale standards (Amersham) and left for 2d
at 4 °C before development. Analysis of autoradiograms
was done by using MCID software (Image Research Inc,
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Ontario, Canada). Densitometric examination of three
striata slices per mouse was conducted with a reference
curve of c.p.m. versus optical density was calculated
from b- emitting [14C] micro-scale standards and used
to quantify the intensity of signal as nCi/g. Moreover,
the background intensity was subtracted from each read-
ing. In the end, data was expressed as mean ± SEM.
signal intensity for the treatment groups. In 0.1% a non-
specific binding was found.
Catecholamine quantification by high performance liquid
chromatography (HPLC)
Analysis was performed by sending tissue pieces to
CMN/KC Neurochemistry Core Lab in Vanderbilt
University for HPLC analysis. Brain sections were
homogenized in 200–750 μl of 0.1 M TCA (10−2 M so-
dium acetate, 10−4 M EDTA, 10.5% methanol). Samples
were centrifuged at 10000 g for 20 min. Supernatant was
removed, the pellet saved for protein analysis. Catechol-
amines were analyzed by using a specific HPLC assay
with an Antec Decade II (oxidation: 0.5) electrochemical
detector operated at 33 °C. Supernatant samples were
injected by utilizing a Water 717+ autosampler onto a
Phenomenex Nucleosil (5u, 100A) C18 HPLC column
(150x4.60 mm). Then, analytes were eluted with a
mobile phase (89.5% 0.1 M TCA, 10−2 M sodium acet-
ate, 10−4 M EDTA, 10.5% methanol) followed by delivery
of the solvent at 0.8 ml/min with a Waters 515 HPLC
pump. Analytes were examined in the following order:
3,4-dihydroxyphenylacetic acid (DOPAC), dopamine
(DA), homovanillic acid (HVA). For HPLC control and
data acquisition Waters Empower software was used.
Total protein for each sample was determined (Peirce
BCA protein assay). Catecholamines values were
expressed as ng analyte/mg total protein.
Immunohistochemistry in human and mouse SN and
striatum reveals Lewy-like pathology
4 μm formalin-fixed paraffin-embedded human brain tis-
sue sections were dewaxed in 5 changes of xylene then
along with 40 μm formalin-fixed mouse brain sections
were brought down to water through graded alcohols.
Sections were exposed to proteinase K (Enzo Life
Sciences, Farmingdale, NY) (1:100 for 15 min at 37 °C
water followed by 5 min at room temperature). Antigen
retrieval was performed using citrate buffer (98 °C for
20 min followed by 20 min at room temperature).
Endogenous peroxidase activity was quenched with 3%
hydrogen peroxide.
To detect human aSyn, sections were incubated with
primary antibody LB509 (Thermo Fisher Scientific, cat#
180215) at a dilution of 1:500 overnight at 4 °C. For de-
tection of the phosphorylated form of aSyn at serine 129
(pSer129) sections were incubated in formic acid for
5 min before proteinase K digestion as described above,
prior to incubation with primary antibody 81A (Biole-
gend, cat #825701) at a dilution of 1:8000 for 1 h at
room temperature. Following incubation with secondary
antibodies staining was detected using an ImmPRESS
Alkaline Phosphatase polymer kit (Vector Laboratories,
Burlington, ON) and colour development with Warp
Red (Biocare Medical, Concord, CA). Finally, sections
were counterstained with Mayer’s Hematoxylin,
dehydrated in alcohols, cleared in xylene and mounted.
Exclusion of animals from analysis
Seven animals of the AAV1/2-A53T-aSyn group were
excluded from analysis after verification of an unsuccess-
ful AAV1/2 injection into the SN by evaluation of
double immunofluorescence stainings against TH/aSyn
depicted by lack of co-localization of the A53T aSyn pro-
tein with TH+ dopaminergic neurons in the SN. For
technical reasons one AAV1/2-EV exposed mouse was
excluded from the DAT autoradiography analysis; one
AAV1/2-A53T-aSyn exposed mouse was excluded from
analysis of DA metabolites (2 mice for AAV1/2-A53T-
aSyn DOPAC) another mouse from AAV1/2-EV group
(2 mice DOPAC).
Statistical analysis
For statistical analysis the distribution of each set of
values was investigated via Q-Q-plots. For normal
distributed data parametric methods were utilized, in
case of different variances the Welch’s correction was
used, for non-normal distributed data non-parametric
methods were employed as statistical tests. For the
cylinder test, analysis of striatal TH+ optical density,
stereological estimation of SN cell counts the para-
metric two-tailed t-test was used, the analysis of DAT
binding was performed with Welch’s t-test because of
different variances. In case of HPLC measurements
non-parametric Mann-Whitney test was implemented.
*P < 0.05, **P < 0.01, ***P < 0.001 were considered as
significant P-values.
Results
Unilateral AAV1/2-A53T-aSyn delivery into the substantia
nigra leads to behavioral deficits in mice
To examine if unilateral AAV1/2-A53T-aSyn injection
results in a measurable behavioural deficit in mice, we
assessed motor behavior by the cylinder test at two time
points, 5 and 9 weeks, during the 10 week in-life phase
of the experiment. A significant asymmetry of forepaw
use with preference for the right side (ipsilateral to
AAV1/2-A53T-aSyn injection) was found in AAV1/2-
A53T-aSyn mice compared to the AAV1/2-EV control
group (mean ± SEM; week 5: AAV1/2-A53T-aSyn 65 ± 3%
and AAV1/2-EV 48 ± 2%, t(34) = 4.313, P = 0.0001; week
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9: AAV1/2-A53T-aSyn 63 ± 4% and AAV1/2-EV 50 ± 3%,
t(34) = 2.335, P = 0.0256) (Fig. 1a).
Degeneration of nigrostriatal pathways after AAV1/2-
A53T-aSyn injection into the substantia nigra
AAV1/2-A53T-aSyn delivery into the SN resulted in a
widespread expression of the transgene covering the
whole SN (Fig. 1b). Ten weeks after AAV1/2-A53T-aSyn
injection, a corresponding A53T-aSyn labeling of ipsilateral
striatal fibers was detected (Fig. 1c). At the same time most
of the remaining TH+ SN neurons co-localized with
human A53T-aSyn as depicted by double immunofluores-
cence staining thus showing a production of the A53T-
aSyn transgene by dopaminergic neurons (Fig. 1d-f).
Moreover, human aSyn + aggregates were located in the
cytoplasm of TH+ SN cells (Fig. 1g-i). As expected, human
A53T-aSyn expression was not observed in mice after EV
delivery (Fig. 1j-l).
Fig. 1 AAV1/2-A53T-aSyn SN injection leads to motor deficits and widespread aSyn expression and aggregation. a Unilateral AAV1/2-A53T-aSyn
delivery leads to a significant asymmetry of forepaw use with preference of the ipsilateral forepaw relative to the side of injection as compared to
AAV1/2-EV control mice. This behavioral deficit was visible at 5 and 9 weeks after AAV1/2 injection (mean ± SEM). b By immunofluorescence
staining of mouse midbrain sections, widespread human A53T-aSyn protein (green) could be detected in the ipsilateral SN (il) 10 weeks after
AAV1/2-A53T-aSyn injection (cl = contralateral). c Mutated A53T-aSyn protein (green) was found in the ipsilateral striatum (il) 10 weeks after
delivery of AAV1/2-A53T-aSyn in the SN thus indicating a transport of this protein along the nigrostriatal tract. d-f Double immunofluorescence
staining of AAV1/2-A53T-aSyn treated mouse SN depicting TH+ dopaminergic neurons (red) (d) and A53T-aSyn transgenic protein (green) (e) that
co-localize (f). g-i High magnification of a TH+ dopaminergic neuron in the SN (red) (g). The same neuron is stained for mutated A53T-aSyn
(green) (h). Aggregates of mutated A53T-aSyn protein can be detected in the cytoplasm of this neuron (arrows) (h, i). j-l) TH+ neurons that were
injected with AAV1/2-EV (j) do not express human A53T-aSyn after 10 weeks (k, l). *P < 0.05; ***P < 0.001
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The extent of nigrostriatal degeneration after AAV1/2-
A53T-aSyn injection was determined (10 weeks post
AAV1/2 injection) by quantification of SN neuronal cells
(dopaminergic, by TH labeling and total neuron popula-
tion by NeuN labeling) and dopaminergic innervation of
striatum (TH immunoreactivity and DAT binding)
(Fig. 2). Unbiased stereology revealed that the estimated
number of TH+ dopaminergic neurons in the ipsilateral
SN was significantly lower in AAV1/2-A53T-aSyn
treated mice compared to AAV1/2-EV injected controls:
5270 ± 374 cells and 7903 ± 271 cells, respectively (mean
± SEM; t(11) = 5.810, P = 0.0001) (Fig. 2a-c). Quantifica-
tion of total neuronal number in the SN showed a
corresponding, significant reduction of neurons in the
ipsilateral SN of AAV1/2-A53T-aSyn mice (11434 ± 441
and AAV1/2-EV 16461 ± 640; t(6) = 6.460; P = 0.0007)
(Fig. 2d-f ). Additionally, we investigated the relative op-
tical density of TH+ striatal dopaminergic fibers
(Fig. 2g-i). In AAV1/2-EV exposed mice the optical
density of TH+ fibers of the ipsilateral, injected side was
98 ± 5% relative to the contralateral side, while in con-
trast, AAV1/2-A53T-aSyn injection led to a decrease of
the ipsilateral striatal TH+ optical density to 79 ± 7%
relative to the contralateral side. Comparing these re-
sults, a significant reduction of the TH+ optical density
in AAV1/2-A53T-aSyn mice by 20% from AAV1/2-EV
mice was evident (t(17) = 2.269, P = 0.0366). Addition-
ally, analyses of DAT binding by autoradiography
Fig. 2 AAV1/2-A53T-aSyn administration in the SN causes neurodegeneration in the nigrostriatal tract. a-c Immunohistochemical staining of the
injected, right SN for TH+ dopaminergic neurons. 10 weeks after administration of AAV1/2 into the SN a significant difference of TH+ dopaminergic
neuronal cell number is visible comparing AAV1/2-EV (a) to AAV1/2-A53T-aSyn treated mice (b). AAV1/2-A53T-aSyn (white bar) induces a significant
reduction of TH+ neurons by ~33% as compared to AAV1/2-EV mice (black bar) (mean ± SEM) (c). d-f) At the same timepoint a significant reduction
of total NeuN+ neurons by ~31% was found in AAV1/2-A53T-aSyn injected mice as compared to AAV1/2-EV control mice (mean ± SEM). g-i TH
immunohistochemical staining of AAV1/2-EV delivered striatum (g). AAV1/2-A53T-aSyn injection in the SN leads to an ipsilateral decrease of the optical
density by ~20% as compared to AAV1/2-EV mice (mean ± SEM) (h, i). j-l) Images of striatal DAT binding by autoradiography reflects comparable
reduction of striatal dopaminergic fibers by ~29% in AAV1/2-A53T-aSyn as compared to AAV1/2-EV treated mice (mean ± SEM). *P < 0.05;
**P < 0.01; ***P < 0.001
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revealed a significant reduction of presynaptic DAT in
AAV1/2-A53T-aSyn injected striatum by 29% from
AAV1/2-EV treated mice (mean ± SEM; AAV1/2-A53T-
aSyn 62 ± 8% and AAV1/2-EV 87 ± 2%, t(16.09) = 3.063,
P = 0.0074) (Fig. 2j-l).
Reduction of striatal neurotransmitter level and increase
of dopaminergic metabolite turnover in AAV1/2-A53T-
aSyn injected mice
For examination of dopaminergic neurotransmitter and
metabolite levels, striatal HPLC was performed and ana-
lyzed for DA and the metabolites DOPAC and HVA
(Fig. 3). Ten weeks after AAV1/2-A53T-aSyn SN
injection a significant reduction of striatal DA level to
60 ± 9% relative to the contralateral side was observed.
This represented a significant decrease of 38% compared
to the EV control group, 96 ± 4% of the contralateral side
(P < 0.001) (Fig. 3a). Additionally, a decrease of DOPAC
of 33% was seen in AAV1/2-A53T-aSyn treated mice (112
± 6%) as compared to EV controls (76 ± 10%; P < 0.01)
(Fig. 3b). At the same time point elevated HVA/DA level
of 60% (162 ± 16% vs 101 ± 3%) was found in AAV1/2-
A53T-aSyn expressing mice indicative for a significantly
higher DA turnover compared to the AAV1/2-EV group
(P < 0.001) (Fig. 3c).
AAV1/2-A53T-aSyn mice develop Lewy-like pathology
There was no positive immunostaining by the LB509,
raised against human Lewy body aSyn, in mouse brain
injected with AAV1/2-EV (Fig. 4a) or in human control
SN (Fig. 4b) indicating that the immunohistochemical
methods used to demonstrate human aSyn (including
proteinase K digestion) do not detect physiological aSyn.
In contrast, in animals injected with AAV1/2-A53T-aSyn
there was a strong signal for aSyn in the SN of the ipsi-
lateral hemisphere (Fig. 4c). High power microscopy
revealed several densely labelled cells within the mouse
SN (Fig. 4d). Human PD nigral Lewy bodies stained
using the same method are provided for comparison
(Fig. 4e). Similarly, several structures were noted in
mouse brain (Fig. 4f ) exhibiting a morphology consistent
with Lewy neurites in human PD brain (Fig. 4g).
Additionally, staining for Ser129 phosphorylated aSyn
after proteinase K digestion was performed (Fig. 5). In
human control SN no positive immunostaining for
pSer129 aSyn was detected, indicating that the immuno-
histochemical method used does not detect any
endogenous physiologic phosphorylated Ser129 aSyn
(Fig. 5a). In contrast, AAV1/2-A53T-aSyn injected
mouse SN showed densely labelled pSer129 aSyn posi-
tive cells (Fig. 5b) resembling pSer129 aSyn positive cells
in human PD brain (Fig. 5c). Moreover, pSer129 aSyn
positive Lewy-like neurites were observed in AAV1/2-
A53T-aSyn mouse SN (Fig. 5d) as well as in human PD
tissue (Fig. 5e). Furthermore, aSyn (LB509) positive
dystrophic neurites were detected in the striatum of
AAV1/2-A53T-aSyn injected mice (Fig. 6)
Discussion
The aim of this study was to generate a mouse model
for PD that develops behavioural deficits and histopatho-
logical hallmarks resembling the human disease within a
practical experimental time frame. We demonstrated
that unilateral injection of AAV1/2 containing human
mutated A53T-aSyn into the SN induced a widespread
overexpression of A53T-aSyn in dopaminergic SN neu-
rons that led to neurodegeneration, dopaminergic fiber
loss and decrease of dopaminergic neurotransmitter in
the striatum within 10 weeks. Moreover, the degener-
ation of the nigrostriatal system was concomitant with
early motor impairment in the cylinder test at 5 weeks
after AAV1/2 injection. This was accompanied by accu-
mulation of human aSyn aggregates in the SN. The
novelty of this model though is the presence of struc-
tures that are similar to Lewy bodies and neurites from
human PD brain, from a morphological perspective.
Our findings that AAV1/2 can induce A53T-aSyn over-
expression in dopaminergic SN neurons are comparable
Fig. 3 AAV1/2-A53T-aSyn SN delivery results in reduction of DA and higher DA turnover. a-c Diagrams show HPLC analyses of DA and
dopaminergic metabolite levels of mouse striatum. Each bar represents the relative level in percent comparing the right (injected) side to the
contralateral (non-injected side). 10 weeks after AAV1/2 injection a significant reduction of DA level is visible in AAV1/2-A53T-aSyn mice (white
bar) as compared to the AAV1/2-EV group (black bar) (a). A significant reduction of DOPAC is also found in AAV1/2-A53T-aSyn treated animal
(b). The elevated ratio of HVA/DA (c) indicates a higher DA turnover in AAV1/2-A53T-aSyn mice. **P < 0.01; ***P < 0.001
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Fig. 4 AAV1/2-A53T-aSyn SN develop insoluble aSyn + aggregates with Lewy-like pathology. a-g Immunhistochemical staining for aSyn with Lewy
body specific LB509 antibody after proteinase K digestion. While AAV1/2-EV control (a) and human control SN (b) do not show any positive aSyn
labelling, AAV1/2-A53T-aSyn injected mice maintain a widespread aSyn positivity after proteinase K digestion (c) that is located in perikarya (d)
and in neurites (f). From a morphological perspective, these findings resemble the situation found in human PD sections corresponding to a
Lewy-like pathology (e, g)
Fig. 5 AAV1/2-A53T-aSyn SN develop insoluble pSer129 aSyn with Lewy-like pathology. There was no positive immunostaining for pSer129 aSyn
in human control nigra (a). In contrast, in animals injected with AAV1/2-A53T-aSyn there was a strong signal for pSer129 aSyn in the SN of the
ipsilateral hemisphere including several densely labelled cells (b). Human PD nigral Lewy bodies stained with the same method are provided for
comparison (c). Similarly, several structures were noted in mouse brain (d) with morphology consistent with Lewy neurites in human PD brain (e)
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to previous data from the PD rat model generated by SN
injection of the same AAV1/2 viral vector. Moreover, as
with the related rat PD model, transport of the A53T-aSyn
from the SN neurons to the striatum was observed in
AAV1/2-A53T-aSyn injected mice, indicating that the
A53T-aSyn protein has the capability to be transported
along the nigrostriatal tract [14]. Thus, as in the AAV1/2-
A53T-aSyn rat model, we could show that the AAV1/2
construct was highly effective in mice regarding the cover-
age of the SN DA neurons and its axonal transport along
the nigrostratal tract.
There is high construct validity in the AAV-aSyn
models of PD. They produce degeneration and dysfunc-
tion based on the core molecular feature of the clinical
disease: toxicity associated with accumulation of aber-
rant aSyn. The definitive detection of pathological aSyn
or Lewy bodies/neurites in the SN and other structures
(e.g. amygdala, locus coeruleus) involves applying a gold
standard histological methodology [2] utilizing protein-
ase K digestion [20] and LB509 antibody labeling proce-
dures. In human, a positive result in this assay provides
support for the postmortem diagnosis of PD. We applied
this method of pathological aSyn detection in midbrain
tissue sections derived from the mouse model alongside
a confirmed human PD case and an aged matched con-
trol. We show that the aged-matched control case did
not show any detectable levels of aSyn, likely due to
clearing of physiological aSyn by proteinase K digestion.
In contrast, the PD case showed abundant aSyn positive
inclusions within melanized SN neurons and the
presence of aSyn positive neurites. Similarly, the mouse
tissue showed extensive aSyn accumulation in structures
resembling both SN neurons and neurites. Thus, we
demonstrate that in the AAV1/2-A53T-aSyn mouse, the
SN develops proteinase K resistant structures with a
morphology resembling Lewy pathology observed in
humans, highlighting the histopathological similarity of
aggregates induced in this mouse PD model to those in
human PD. Although cytoplasmic aSyn aggregates of cell
bodies have been observed in other PD mouse models,
histological insolubility of these aggregates and explicit
morphological similarity to human PD Lewy pathology
was not shown [21, 24]. Phosphorylation of aSyn at Ser129
is considered a specific marker of α-synucleinopathies that
promotes aSyn fibril formation [11]. Additionally, it has
been shown that misfolding and hyperphosphorylation of
aSyn might lead to central locomotor dysfunction in the
(Thy1)- h[A30P]αSyn transgenic mouse model for an α-
synucleinopathy [19]. We therefore analyzed the AAV1/2-
A53T-aSyn mouse for Ser129 aSyn phosphorylation and
found positive profiles in the SN again demonstrating the
authenticity of pathologic aSyn aggregates in this mouse
PD model.
We also found a significant degeneration of dopamin-
ergic SN neurons, with a 33% reduction in AAV1/2-
A53T-aSyn treated mice as compared to the EV control
group. This was accompanied by significant loss of
nigrostriatal dopaminergic fibers measured by striatal
TH staining and DAT binding, reduced by 20% and 29%,
respectively, thus recapitulating a histopathological hall-
mark of human PD and providing support for the model
showing a high degree of face validity. Interestingly, in
human PD, the onset of nigrostriatal degeneration pre-
cedes the occurrence of motor impairment with an esti-
mated ~30% loss of SN neurons, and an even higher loss
of striatal terminals, evident prior to motor symptom
onset [15] (for review see Cheng et al., 2010 [6]). In
contrast, in rodent models of PD, motor features can
develop in the absence of significant overt nigrostriatal
degeneration [13], perhaps due to the relatively intense
burden of synucleinopathy in the otherwise intact
nigrostriatal dopaminergic system. Indeed, although sev-
eral AAV overexpression-based PD mouse models exist,
either with overexpression of mutated or non-mutated
aSyn, one of the main problems most of these models
face so far is that they express, at best, limited nigros-
triatal degeneration. Thus, two AAV models overex-
pressing either mutated A53T-aSyn (serotype not
mentioned) [8] or human wt-aSyn (AAV2) [28] did not
show degeneration of SN dopaminergic neurons even
after 7 and 12 weeks post AAV injection. Similarly, in St.
Martin et al. (2006), expression of human wt-aSyn by
AAV (serotype not mentioned), produced no significant
dopaminergic SN neuron loss after 12 weeks nor striatal
dopaminergic fiber denervation of the striatum after
Fig. 6 AAV1/2-A53T-aSyn striatum demonstrates LB509+ dystrophic
neurites. Striatum of AAV1/2-A53T-aSyn injected mice were stained
with antibody directed against LB509. LB509+ aSyn dystrophic
neurites (arrows) are shown
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24 weeks [25]. In contrast, Yasuda et al. (2009), however,
were able to show that AAV1-produced human wt-aSyn,
delivered to the mouse SN, resulted in a significant loss
in SN DA neurons at 8 weeks, however, no deficits were
shown at the level of the striatum [30]. These reports
are opposed to the finding in our PD model with a de-
crease of 38% in DA and 33% in DOPAC levels in the
AAV1/2-A53T-aSyn delivered hemisphere compared to
control EV injected mice. Two AAV aSyn based PD
mouse models, with an AAV2 component, have, in a
manner similar to the model we present here, presented
a clear loss of dopaminergic SN neurons in a relatively
short time frame after AAV administration. In the first
study, Oliveras-Salva et al. (2013) showed, in a viral con-
centration dependent manner, that AAV2/7 (wt and
A53T-aSyn) delivery resulted in loss of TH+ SN cells
that was observed as early as 4 weeks (by 57%) with a
maximal loss at 8 weeks after injection (by 82%). This
was accompanied by a reduction in TH+ immunoreac-
tivity in the striatum [21]. In the second study, Song et
al. (2015) showed that AAV2/1-human wt-aSyn exposed
mice showed a significant reduction in SN DA neurons
after 8 weeks (by 34%) and 12 weeks (by 50%) that was
accompanied by a decrease of striatal TH+ fibers and
DA levels in the affected hemisphere, compared to
AAV2/1-GFP controls [24]. Interestingly, and in contrast
to our own report here, in the AAV2/7 and AAV2/1
models, a significant deficit in behavior was only found
at later stages, from 12 weeks on, i.e. after the degener-
ation had occurred, and indeed, at a level exceeding
what would be expected in PD patients upon first obser-
vation of motor symptoms. This is reminiscent of the
6-hydroxydopamine and 1-Methyl-4-phenyl-1,2,3,6-tet-
rahydropyridin toxin based models which require such
levels of degeneration in order to produce spontaneous
motor impairments.
There are limitations to this study. Firstly, the model
necessitates a level of expertise to be able to deliver
AAV1/2, by intracerebral injection, to the mouse SN,
thus in our hands we mistargeted the SN in 16.3% of the
cases. Secondly, reversibility of behavioural deficits using
clinically defined treatments (e.g. L-DOPA, ropinirole)
was not conducted and thereby the models predictive
validity has yet to be determined. Thirdly, this study
does not include a control group expressing a control
protein. It has already been shown in the AAV1/2-
A53T-aSyn rat PD model that a high titer of AAV1/2
containing green fluorescent protein (AAV1/2-GFP)
causes neurodegeneration but significantly less than
compared to AAV1/2-A53T-aSyn treated rats. Moreover,
no loss of striatal TH-immunoreactivity was observed in
AAV1/2-GFP rats, thus indicating that the toxicity of
AAV1/2-GFP was not responsible for all the A53T-aSyn
induced damage [14]. Nonetheless, it cannot be excluded
that in the AAV1/2-A53T-aSyn mouse model the demise
of dopaminergic neurons is at least to some extent inde-
pendent from pathologic A53T-aSyn. Finally, although
LB509 positive dystrophic neurites have been detected in
the striatum of AAV1/2-A53T-aSyn mice, pathological,
insoluble aSyn deposition in presynapses, that have been
seen in A53T-aSyn transgenic mice [26], have not been
addressed in this work.
Conclusions
In summary, with misfolded aSyn as a key player in the
pathogenesis of PD, the need for a mouse PD model with
a Lewy-like α-synucleinopathy is clear. We show that the
AAV1/2-A53T-aSyn mouse fulfills several criteria required
of a viral vector mediated PD model, that is a) sustained
production of the transgene in dopaminergic neurons, b)
transport of AAV1/2 produced pathological aSyn to the
striatum, c) degeneration of the nigrostriatal tract, d)
histopathological similarities to human PD (Lewy-like
pathology), e) behavioral deficits and f) relatively short
timeframe to produce behavioral deficits and postmortem
endpoints (within 2 months). This novel PD model is the
first, to our knowledge, reporting all these characteristics,
and is now in a position to be further analyzed and trans-
ferred to transgenic and knockout mice for unravelling
molecular mechanisms of PD and preclinical testing of
disease modifying therapies.
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